It is made available under a CC-BY-NC-ND 4.0 International license .

1 Revealing the biology behind MRI signatures in high grade

2 glioma

- 3 Erika M Lewis ¹, Lingchao Mao ², Lujia Wang ², Kristin R Swanson ^{3, 4}, Ramon F Barajas ^{5,6,7},
- 4 Jing Li², Nhan L Tran^{4, 8}, Leland S Hu^{3, 9, 10*}, Christopher L Plaisier^{1*}
- 5
- ¹ School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ,
 85287, USA.
- ⁸ ² H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of
- 9 Technology, Atlanta, GA, 30332, USA.
- ³ Mathematical Neuro-Oncology Lab, Department of Neurological Surgery, Mayo Clinic,
- 11 Phoenix, AZ, 85054, USA.
- ⁴ Department of Neurosurgery, Mayo Clinic, Phoenix, AZ, 85054, USA.
- ⁵ Advanced Imaging Research Center, Oregon Health & Sciences University, USA.
- ⁶ Department of Radiology, Neuroradiology Section, Oregon Health & Sciences University, USA.
- ⁷ Knight Cancer Institute, Oregon Health & Sciences University, USA.
- ⁸ Department of Cancer Biology, Mayo Clinic, Phoenix, AZ, 85054, USA.
- ⁹ Department of Radiology, Mayo Clinic, Phoenix, AZ, 85054, USA.
- ¹⁰ School of Computing, Informatics, and Decision Systems Engineering, Arizona State
- 19 University, Tempe, AZ, 85281, USA.
- 20
- 21 *To whom correspondence should be addressed: <u>Hu.Leland@mayo.edu</u> (L.S.H.) and
- 22 plaisier@asu.edu (C.L.P.)

It is made available under a CC-BY-NC-ND 4.0 International license .

23 Abstract

- 24 Magnetic resonance imaging (MRI) measurements are routinely collected during the treatment
- of high-grade gliomas (HGGs) to characterize tumor boundaries and guide surgical tumor
- 26 resection. Using spatially matched MRI and transcriptomics we discovered HGG tumor biology
- 27 captured by MRI measurements. We strategically overlaid the spatially matched omics
- characterizations onto a pre-existing transcriptional map of glioblastoma multiforme (GBM) to
- 29 enhance the robustness of our analyses. We discovered that T1+C measurements, designed to
- 30 capture vasculature and blood brain barrier (BBB) breakdown and subsequent contrast
- 31 extravasation, also indirectly reveal immune cell infiltration. The disruption of the vasculature
- 32 and BBB within the tumor creates a permissive infiltrative environment that enables the
- transmigration of anti-inflammatory macrophages into tumors. These relationships were
- validated through histology and enrichment of genes associated with immune cell transmigration
- and proliferation. Additionally, T2-weighted (T2W) and mean diffusivity (MD) measurements
- ³⁶ were associated with angiogenesis and validated using histology and enrichment of genes
- 37 involved in neovascularization. Furthermore, we establish an unbiased approach for identifying
- 38 additional linkages between MRI measurements and tumor biology in future studies, particularly
- 39 with the integration of novel MRI techniques. Lastly, we illustrated how noninvasive MRI can be
- 40 used to map HGG biology spatially across a tumor, and this provides a platform to develop
- 41 diagnostics, prognostics, or treatment efficacy biomarkers to improve patient outcomes.
- 42
- 43 **Keywords:** MRI, tumor biology, immune infiltration, angiogenesis, image localized biopsies

It is made available under a CC-BY-NC-ND 4.0 International license .

44 Introduction

45 Conventional magnetic resonance imaging (MRI) is a cornerstone for noninvasively diagnosing and devising treatment strategies for deadly high-grade glioma (HGG) tumors. Currently, MRI is 46 primarily used to establish tumor boundaries that are readily observed as regions where the 47 48 blood-brain-barrier (BBB) has been disrupted allowing for MRI contrast extravasation into the 49 tumor interstitial space (1). Accurately delineating tumor boundaries is crucial for determining tumor burden, which translates clinically to the extent of surgical resection (2). The ubiquitous 50 51 use of MRI in the clinical management of HGG tumors, coupled with the development of new 52 MRI techniques, demands further study to elucidate the biological phenomena captured by imaging HGG tumors. 53

54 MRI measurements from HGG tumors have also been linked to tumor heterogeneity (3, 4),

tumor percentage (5), cellular density (6, 7), and found to be predictive in prognostic and
 recurrence models (8–10). Simultaneous imaging and molecular characterization provide a

57 platform for linking noninvasive biophysical imaging patterns to their molecular underpinnings.

58 Examples include associations with EGFR mutational status (11) and CD49 immune cell

59 presence (12) onto three-dimensional representations of a tumor. We hypothesize that

additional insights into tumor biology can be extracted from MRI through integration of imaging

61 and molecular measurements.

62 We conducted a system level integrative study to reveal the clinically relevant aspects of HGG

tumor biology that can be captured through noninvasive MRI measurements. Establishing

64 connections between MRI measurements and HGG tumor biology requires a spatially matched

quantification of MRI alongside omics-scale molecular characterization. We generated a cohort

of spatially matched MRI and transcriptomics characterized contrast enhancing (CE) HGG

tumors (13). In the spatially matched cohort, we collected MRI measurements for T1-weighted

68 contrast-enhanced (T1+C), T2-weighted (T2W), and two diffusion weighted imaging metrics:

69 fractional anisotropy (FA), and mean diffusivity (MD). T1+C utilizes a contrast agent to identify

areas of BBB disruption by registering where the contrast agent leaks out of vasculature into the surrounding tissue interstitia (14). T1+C is generally used as a surrogate for tumor presence

and to define HGG tumor burden (14). T2W captures tissue water content with bright areas

73 extending past the T1+C signal indicating vasogenic edema (14). An infiltrative tumor can

74 extend into these regions of edema, and T2W is thus valuable alongside T1+C in guiding the

extend into these regions of edema, and 12W is thus valuable alongside 11+C in guiding the extent of surgical resection (14). T1+C and T2W are commonly used to facilitate many aspects

of HGG patient care, including initial diagnosis, treatment planning, and response assessment

77 after first-line therapy. Advanced diffusion-based MRI techniques, such as FA and MD, have

78 gained traction as essential complementary techniques in neuro-oncology. FA is a form of

diffusion tensor imaging (DTI) that measures directionally dependent water diffusion (14). FA

80 values measure perturbation from linear diffusion which is often used to characterize the risk for

tumor infiltration of white matter tracts during pre-surgical mapping (15). MD is a form of

diffusion-weighted imaging (DWI) that measures extracellular bulk water diffusion *(14)*. MD has

classically been used to measure water restriction related to cytotoxic edema and has been

correlated with constrained diffusion due to cellular packing in neuro-oncology (16). Together,

85 these MRI measurements quantify a wide range of biophysical phenomena that could potentially

86 be used as noninvasive proxies for the underlying biology of HGG tumors.

- 87 Collecting spatially matched biopsies and MRI measurements from a tumor is a complex
- surgical undertaking, which leads to smaller cohort sizes. In this study, we boosted the signal in
- 89 our analyses by overlaying the omics characterizations onto a previously constructed
- 90 transcriptional map of glioblastoma multiforme (GBM). The gbmSYGNAL network was
- 91 constructed using multi-omic profiles of 422 patient tumors from The Cancer Genome Atlas
- 92 (TCGA) (17). The 5,194 genes in the gbmSYGNAL network are aggregated into 500 co-
- ⁹³ regulated gene expression signatures (biclusters). Biclusters contain genes that were linked to
- 94 pathways and biological processes through functional enrichment analysis. We then linked
- 95 enriched pathways and biological processes to the hallmarks of cancer (17–20). The hallmarks
- 96 of cancer describe clinically relevant oncogenic functions acquired by all cancer types and are
- 97 especially relevant to HGGs (21). We aim to identify MRI proxies for HGG tumor biology by
- discovering which spatially matched MRI measurements are predictive of clinically relevant
- 99 tumor biology encapsulated within biclusters.

It is made available under a CC-BY-NC-ND 4.0 International license .

100 Methods

101 Patient recruitment and surgical biopsies

- 102 Patient recruitment took place at both Barrow Neurological Institute (BNI) and Mayo Clinic in
- 103 Arizona (MCA) through IRB approved protocols at each institution. Informed consent was
- 104 obtained prior to enrollment. Patients recruited for these studies underwent preoperative
- stereotactic MRI for surgical resection and had a histologically confirmed diagnosis of high-
- grade glioma (grade III or IV) and most of the patient tumors were IDH WT (25 IDH WT and 5
- 107 IDH mutant) (13). Most of the patient tumors were primary tumors (n = 23) and a smaller subset
- 108 were recurrent tumors (n = 7). Characteristics of the patients, tumors and biopsies can be found
- in **Table S1**. The smallest possible diameter craniotomies were used to minimize brain shift. An
- average of 4-5 biopsies were collected from contrast-enhancing (CE) tumor regions separated
- by at least one cm using stereotactic surgical resection guided by conventional preoperative
- 112 MRI (T1+C and T2W) (13). Biopsy locations were recorded via screen capture to allow co-
- 113 registration of all MRI measurements.

114 Conventional MRI to capture T1+C and T2W and general acquisition conditions

- 115 Patients were imaged 24 hours before stereotactic surgery using a 3T MRI scanner (Sigma
- 116 HDx; GE-Healthcare Waukesha Milwaukee; Ingenia, Philips Healthcare, Best, Netherlands;
- 117 Magnetome Skyra; Siemens Healthcare, Erlangen Germany). Conventional MRI included
- standard pre- and post-contrast T1-weighted (T1, T1+C, respectively) and pre-contrast T2-
- 119 weighted (T2W) sequences as previously described (13). Briefly, T1 and T1+C images were
- 120 acquired using inversion-recover prepped (IR-prepped) spoiled gradient recalled-echo (SPGR)
- 121 (T1/TR/TE = 300/6.8/2.8 ms; matrix = 320 x 224; FOV = 26 cm; thickness = 2 mm). The
- 122 gadolinium based contrast agent (GBCA) was gadobenate dimeglumine for patients recruited at
- 123 BNI and gadobutrol for patients recruited at MCA. T2W images were acquired using fast-spin-
- 124 echo (FSE) (TR/TE = 5133/78 ms; matrix = 320 x 192; FOV = 26 cm; thickness = 2 mm).

125 **DTI was used to capture MD and FA**

- 126 DTI was performed using Spin-Echo Echo-planar imaging (EPI) [TR/TE 10,000/85.2 ms, matrix
- 127 256 x 256; FOV 30 cm, 3 mm slice, 30 directions, ASSET, B = 0,1000]. The DTI DICOM files
- 128 were converted into NIfTI format using MRIConvert
- 129 (http://lcni.uoregon.edu/downloads/mriconvert). DTI parametric maps were calculated using FSL
- 130 (22) to generate whole-brain maps of MD and FA (13, 23).

131 Image co-registration

- 132 Each MRI measurement was co-registered to the DTI B0 anatomical image volume using tools
- 133 from ITK (24) and IB Suite (Imaging Biometrics, LLC) (13). This approach to co-registration
- 134 minimizes potential distortion errors from resampling that can adversely affect DTI metrics. The
- 135 co-registered data was resampled to an in-plane voxel resolution of ~1.17 mm (256 x 256
- 136 matrix) and a slice thickness of 3 mm.

137 Region of interest (ROI) generation and image feature extraction

- 138 The stereotactic location recorded for each biopsy during surgery defined a spatially matched
- 139 MRI ROI measuring 8 x 8 x 1 voxels (9.6 x 9.6 x 3 mm). A board-certified neuroradiologist
- 140 (L.S.H.) visually inspected all ROIs to ensure accuracy and that each biopsy specimen was in a

It is made available under a CC-BY-NC-ND 4.0 International license .

- 141 CE region of the tumor (13). Biopsies near potential artifacts (e.g., the floor of the anterior skull
- base, middle cranial fossa superior to the mastoid air cells, or craniectomy plate/screws) or in
- 143 locations expected to yield no tissue (e.g., resection cavity or central necrosis) were excluded
- 144 from the study. The mean value was calculated from the voxels in each biopsy's ROI for each
- 145 MRI imaging technique, and these values were used for subsequent analyses linking MRI and
- 146 transcriptomics.

147 RNA-sequencing of image-localized biopsies

- 148 RNA was extracted from flash frozen tissue, libraries were constructed using the Illumina
- 149 TruSeq v2 RNAseq kit, and paired-end reads were sequenced on an Illumina HiSeq 4000
- 150 sequencer. FASTQ files were aligned to the human transcriptome (GRCh38.p37) using STAR,
- read counts were compiled using htseq-count, and batch effect was corrected using ComBat-
- 152 seq as previously described *(13)*. Tumor purity was computed for all 75 samples with whole
- 153 exome sequencing (WES) as previously described (13).

154 Revising biclusters for use with RNA-seq data

- 155 The first principal component corrected for sign (eigengenes) for each gbmSYGNAL bicluster
- 156 was computed from the 75 CE MRI samples with RNA-seq, tumor purity, and MRI
- measurements (17, 25). Mixed effects models (MEMs) from the statsmodels package (26) were
- used to associate each bicluster eigengene with the expression of each constituent gene across
- the 75 samples, using patient ID, tumor purity and IDH mutational status as random effects, and
- 160 patient ID was used to account for repeated samples collected from the same patient tumor.
- 161 Genes with a positive beta value ($\beta > 0$) and significant association (p-value ≤ 0.05) with the
- eigengene were included in the revised bicluster gene set definitions. Revised biclusters with at
- least five genes and an eigengene with a first principal component (PC1) variance explained \geq
- 164 0.3 were included in subsequent analyses.

165 Associating biclusters with MRI measurements

- 166 Revised bicluster eigengenes were tested for association with MRI measurements across the
- 167 75 samples using a MEM with patient ID, tumor purity, and IDH mutational status as random
- 168 effects, and patient ID was used to account for repeated samples collected from the same
- patient tumor. Significant eigengene-MRI relationships were defined by a p-value ≤ 0.05 .

170 Linking MRI measurements to the hallmarks of cancer through gbmSYGNAL

- 171 In the construction of gbmSYGNAL, biclusters were associated with GO biological process
- 172 (GO:BP) terms and then linked to the hallmarks of cancer using semantic similarity (17).
- 173 Significant linkage to the hallmarks of cancer was defined as a significant MRI association with
- the bicluster eigengene and a Jiang-Conrath semantic similarity score ≥ 0.7 to a hallmark of
- 175 cancer. For each MRI measurement, hypergeometric enrichment analysis was used to test the
- significance of the overlap between MRI and hallmarks of cancer associated biclusters (17).
- 177 Significant enrichment was defined by a BH-adjusted p-value ≤ 0.05 and an overlap > 0.

178 Linking MRI measurements to patient survival through gbmSYGNAL

- 179 In constructing gbmSYGNAL, biclusters were linked to patient survival using Cox proportional
- 180 hazards regression with patient age as a covariate and replicated in at least one of three
- independent validation cohorts used in Plaisier et al., 2016 (17). This study defined a significant

It is made available under a CC-BY-NC-ND 4.0 International license .

- linkage between a bicluster and patient survival based on a p-value ≤ 0.05 and the hazard ratio
- in the same direction in all four cohorts (17). For each MRI measurement, hypergeometric
- 184 enrichment analysis was used to test the significance of the enrichment between MRI and
- patient survival associated biclusters (17). Significant enrichment was defined by a BH-adjusted
- 186 p-value ≤ 0.05 and an overlap > 0.

187 Clinical and molecular data for the TCGA GBM cohort

- 188 The Pan-Cancer Atlas consortium contains standardized, normalized, batch-corrected, and
- platform-corrected multi-omics data for 11,080 participant tumors (27). This work used 422
- 190 complete multi-omic GBM patient tumor profiles to validate findings from MRI data. The TCGA
- 191 GBM cohort microarrays were used for RNA expression (n = 422). TCGA aliquot barcodes
- 192 flagged as "do not use" or excluded by pathology review from the Pan-Cancer Atlas Consortium
- 193 were removed from the study. Overall survival (status and time to an event) for patients in the
- 194 cohort were obtained from Liu et al. 2018 (28).

Associating tumor infiltrating lymphocytes (TILs) to revised bicluster eigengenes in TCGA

- 197 Histologically determined quantification of TILs was available for 124 TCGA GBM tumors, where
- a value of 0 indicated TIL absence and values of 1 or 2 indicated TIL presence (29). For each
- 199 revised bicluster eigengene, a t-test was performed comparing bicluster expression to TIL status
- 200 (present vs. absent) across all 124 TCGA patients. Significant associations were determined by
- a BH-adjusted p-value ≤ 0.05. Hypergeometric enrichment analysis was used to test for
- 202 enrichment between TIL and MRI associated biclusters, where significant enrichment was
- 203 defined by a BH-adjusted p-value ≤ 0.05 and an overlap > 0.

204 Deconvoluting immune cell abundance estimates

- 205 The CIBERSORTx deconvolution method was used to estimate immune cell abundance from
- bulk gene expression data (30). The MRI and TCGA cohorts were run through CIBERSORTx to
- 207 estimate immune cell abundance using the LM22 signature matrix (30). Batch correction and
- 208 quantile normalization were disabled, the relative run mode was selected, and 500 permutations
- 209 were performed. Results were restricted to include T-cells (CD8+, CD4+ memory resting, and
- follicular helper), NK cells (resting and activated), and macrophages/microglia (non-activated,
- 211 pro-inflammatory, and anti-inflammatory) to remain consistent with the infiltrating immune cell
- types previously identified in GBM tumors (31–34).

213 Associating immune cell estimates to revised bicluster eigengenes

- 214 Deconvoluted immune cell fraction estimates were compared to bicluster eigengenes. Pearson
- correlations were used to test for associations between deconvoluted immune cell fractions for
- the TCGA cohort, because each patient corresponded to a single sample (27). Associations in
- the MRI cohort were computed using a MEM with patient ID, tumor purity, and IDH mutational
- status as random effects, where patient ID was used to account for repeated samples collected
- from the same patient tumor. Significant associations were identified for both the MRI and
- TCGA cohorts with a BH-adjusted p-value ≤ 0.05 .

221 Isolating hallmark-specific GOBP terms

- For each MRI measurement, the genes from significantly associated revised biclusters were
- aggregated into two gene lists: one for positively associated revised biclusters, and a second

It is made available under a CC-BY-NC-ND 4.0 International license .

- for negatively associated revised biclusters. Genes were removed if they were members of two
- biclusters that had opposite beta value signs with the same MRI measurement (3 genes were
- removed in total). Functional enrichment analysis was performed on each gene list using the
- enrichr module from the gseapy package (35). Significant GO:BP terms were identified with a
- BH-adjusted p-value \leq 0.05 and an overlap ratio of \geq 0.1. Each GO:BP term was individually
- 229 tested for significant semantic similarity with the hallmark(s) of cancer. Hallmark-specific GO:BP
- terms were identified with a Jiang-Conrath semantic similarity score ≥ 0.7. For each MRI
- 231 measurement, GO:BP terms significantly associated with both the MRI measurement and the
- hallmark of cancer ('Self sufficiency in growth signals,' 'Insensitivity to antigrowth signals,' or
- 233 'Tissue invasion and metastasis') were isolated for further study.

Associating vessel markup percentage to revised bicluster eigengenes in TCGA

- 235 Histologically determined percentages of vessel markup were available for 79 TCGA GBM
- tumors (36). A Pearson correlation was performed comparing each bicluster eigengene to
- vessel markup percentage. Significant associations were determined by a p-value ≤ 0.01 .
- 238 Hypergeometric enrichment analysis was used to test for enrichment between vessel and MRI
- associated biclusters, where significant enrichment was defined by a BH-adjusted p-value ≤
- 240 0.05 and an overlap > 0.

241 Calculating percentiles for MRI signal, bicluster expression, and gene expression

- 242 MRI measurements (T1+C), revised bicluster eigengenes (PITA-14, Targetscan-269, and
- Targetscan-541), and transcript levels (CD163) were normalized to scale between 0 and 1
- 244 across six MRI samples from patient BNI152 with RNA-seq, tumor purity, and MRI
- 245 measurements.

It is made available under a CC-BY-NC-ND 4.0 International license .

246 **Results**

247 Cohorts of HGG tumors

248 We collected 75 spatially matched biopsies and MRI measurements from 30 HGG patient

- tumors (the MRI cohort, Figure 1A, Table S1). All 75 biopsies were characterized by RNA-seq
- and exome-seq to discover transcriptional signatures and tumor purity describing the underlying
- composition and molecular changes in each biopsy (13). An average of two and a half image
- localized biopsies (one to six biopsies) were collected from CE tumor regions separated by at
- least one cm, and average tumor purity, i.e., abundance of tumor cells in the biopsy, was $63\% \pm$
- 254 20%. We accounted for the repeated sampling from the same tumor and tumor purity by
- 255 incorporating them into our statistical tests.
- The 30 tumors characterized in the MRI cohort cannot capture the full intertumoral
- heterogeneity observed between HGG tumors (37). We addressed this gap by incorporating the
- TCGA GBM cohort, which extensively profiled the transcriptomes of 422 patient tumors (17, 27).
- 259 Previously we constructed the gbmSYGNAL network (17) to discover co-regulated gene
- 260 expression signatures, or biclusters, that encapsulate the fundamental biological processes
- inherent to GBM tumors (i.e., hallmarks of cancer (18, 19)) (Figure 1A). We leverage the
- biology encapsulated by the 500 biclusters from gbmSYGNAL to enhance the depth and scope
- of our analyses with the MRI cohort. We also used the histological characterization of the TCGA
- GBM cohort to validate associations with immune cell infiltration (29) and angiogenesis (36).
- The integration of these two complementary cohorts culminates in a powerful platform for
- 266 uncovering the HGG tumor biology captured by MRI measurements.

267 Revising gbmSYGNAL biclusters for use with RNA-seq data

- 268 Technological differences between RNA-seq (MRI cohort) and microarray (TCGA cohort) are
- known to cause discrepancies in gene expression for some genes *(38, 39)*. These
- discrepancies led to a lack of positive correlation for a minority of genes within the bicluster
- eigengenes of the MRI cohort (Figure S1A), which can impact downstream analyses. As a
- countermeasure, we devised a series of filters designed to eliminate genes exhibiting
- 273 inconsistent expression patterns between platforms. This intervention was designed to ensure
- that the bicluster eigengene remains a robust representation of its constituent gene variance
- 275 (Figures S1A-D). The implementation of the filters yielded a discernible impact: the exclusion
- of 1,926 genes (out of 5,194) and 33 biclusters (out of 500) from further analyses (**Table S2**).
- For the remaining 467 biclusters there was a reduction in the average number of genes per
- bicluster from 36 ± 11 to 25 ± 8 . Importantly, the filters did not significantly alter the number of
- biclusters associated with each MRI measurement. The filters improved the results of
- downstream functional enrichment analyses (Figures S1E-S1F). In summary, the bicluster
- revision process removed genes marginally co-expressed in RNA-seq to improve bicluster
- coherence and bolstered the signal strength for subsequent functional enrichment analyses.

283 Linking MRI measurements to the hallmarks of cancer

- Our primary goal in these studies was to link MRI measurements to the underlying biology of
- HGG tumors. We first associated MRI measurements to revised bicluster eigengene expression
- using a MEM that corrects for tumor purity, repeated sampling from the same patient tumor, and
- IDH mutational status (MRI \rightarrow bicluster; Figure 1A). Our data showed positive associations

It is made available under a CC-BY-NC-ND 4.0 International license .

- between all MRI measurements and the expression of at least 12 biclusters (Figure 1B, Table
- **S3**). Fewer negative associations were discovered that linked MRI measurements to the
- 290 expression of biclusters (Figure 1B, Table S3).
- Next, we integrated MRI associated biclusters to hallmarks of cancer using relationships 291 previously defined in the gbmSYGNAL network (bicluster \rightarrow hallmark(s) of cancer; Figure 1A) 292 293 (17). Using the transitive property, we linked MRI measurements to the hallmarks of cancer with 294 biclusters as the intermediaries (i.e., MRI \rightarrow bicluster and bicluster \rightarrow hallmarks of cancer, therefore MRI \rightarrow hallmarks of cancer). The biclusters positively associated with MRI were 295 296 significantly enriched with biclusters associated with seven hallmarks of cancer (BH-adjusted pvalue < 0.05, Figure 1C, Table S3). The biclusters positively associated with T1+C were 297 significantly enriched with biclusters associated with the immune-related hallmarks 'Evading 298 299 immune detection' and 'Tumor promoting inflammation,' as well as the growth-related hallmarks 'Insensitivity to antigrowth signals' and 'Self sufficiency in growth signals.' Biclusters positively 300 associated with MD and T2W were significantly enriched with 'Sustained angiogenesis' and 301 302 'Tissue invasion & metastasis' associated biclusters. Biclusters positively associated with T2W 303 also had a significant enrichment with 'Evading apoptosis' hallmark associated biclusters. These results suggest that the MRI measurements (T1+C, MD, and T2W) might be used as 304 305 noninvasive surrogates for seven hallmarks of cancer.
- 306 We also tested for enrichment between MRI and patient survival associated biclusters (Figure
- **1D**, **Table S3**) (17). Biclusters positively associated with T1+C were significantly enriched with
- biclusters that predicted shorter patient survival (BH-adjusted p-value = 4.1×10^{-13}). This
- 309 observation is consistent with other studies that have recognized T1+C as a prognostic tool for
- 310 HGG *(9, 40)*.

311 **T1+C** is associated with increased tumor infiltrating lymphocytes

- The strongest association we observed in this study linked T1+C to biclusters enriched with the
- immune hallmarks of cancer (**Figure 1C**). We validated the association between T1+C and the
- immune hallmarks by testing whether the biclusters positively associated with T1+C were
- 315 significantly enriched with biclusters associated with histologically-determined TILs in the TCGA
- cohort *(29)*. We found that 151 of the 467 revised biclusters were significantly positively
- associated with TILs (T-statistic > 0; BH-adjusted p-value \leq 0.05; **Table S4**). There was a highly
- significant enrichment between the TILs and T1+C associated biclusters (overlap = 125; BH-
- adjusted p-value = 1.1×10^{-12} ; **Figures 2A-D**). This striking overlap of TIL and T1+C associated
- biclusters supports that T1+C could be used as a proxy for tumor immune cell infiltration.

T1+C is associated with deconvoluted signatures of immune cell types

- 322 We then sought to identify the specific immune cell types infiltrating HGG tumors by examining
- associations between biclusters positively linked to T1+C and estimates of immune cell
- abundance. We focused our studies on the infiltrating immune cell types observed in HGG
- tumors (31–34), which included T-cells (CD8+, CD4+ memory resting, and follicular helper), NK
- cells (resting and activated), and macrophages/microglia (non-activated, pro-inflammatory, and
- anti-inflammatory). The choice of these cell types was confirmed by the observation that both T-
- 328 cells and macrophages/microglia were the most abundant immune cell types in the estimates
- 329 for the MRI and TCGA cohorts (**Figures S2A-C**).

It is made available under a CC-BY-NC-ND 4.0 International license .

Next, we tested for associations between the eigengenes from biclusters positively associated 330 331 with T1+C and tumor-level estimates for the abundance of each immune subset (Figures 2E-G; Table S5). Associations between biclusters positively associated with T1+C and infiltrating 332 immune cell estimates were considered significant if they replicated across the two 333 independently collected MRI and TCGA cohorts. No consistent trends were observed for the T-334 cells between the two datasets (Figures 2E & 2H). We did detect a significant positive 335 336 relationship between biclusters positively associated with T1+C and resting NK cells (β-value 337 and correlation coefficient < 0; BH-adjusted p-value \leq 0.05; **Figures 2F & 2I**). The most striking trend we observed was a strong positive relationship between biclusters positively associated 338 339 with T1+C and anti-inflammatory macrophages/microglia (β -value and correlation coefficient > 0; BH-adjusted p-value \leq 0.05, Figures 2G & 2J). The increased infiltration of anti-inflammatory 340 341 macrophages/microglia is strongly supported by literature reporting that these cells typically 342 comprise a substantial fraction of HGG tumor bulk (31–34). A separate study also identified an 343 increase of bone marrow-derived macrophages/microglia in the CE core of HGG tumors where 344 T1+C signal is elevated, further supporting the link between T1+C and the presence of 345 macrophages/microglia (41). Collectively, these findings provide strong evidence that elevated 346 T1+C levels are linked to an increased presence of anti-inflammatory macrophages/microglia within the tumor microenvironment. 347

Leaky vasculature and BBB breakdown leads to influx of contrast agent and immune cells

Our analyses showed evidence for a relationship between T1+C signal and tumor immune cell 350 infiltration, but the underlying biophysical mechanism driving this association still needs to be 351 352 explained. The biophysics of T1+C signal is based on the intravenous injection of a GBCA that is used for both enhancement of vasculature and to visualize HGG tumor burden (14). As HGG 353 354 tumors grow, they crush the surrounding tissue and actively secrete enzymes that collectively 355 lead to a loss in integrity of both the vasculature and BBB at various regions around the tumor (42-46). This leakiness allows GBCA out of the vasculature and across the BBB, where it 356 generates a T1+C signal (Figure 2K). The genes from T1+C associated biclusters revealed the 357 mechanisms for the breakdown of vasculature and BBB, and subsequent immune cell 358 transmigration (Figure 2K). The biclusters included the angiogenic factors ANGPT2, FGFBP2, 359 360 FGF20, and TNF that loosen the walls of vasculature and cell contacts of the BBB in brain 361 metastases (43, 46). Physical crushing due to tumor growth in a confined space increases vasculature and BBB breakdown, allowing blood vessel contents to seep into the central 362 363 nervous system (CNS) (45). The cell adhesion molecule VCAM1 mediates the adhesion of 364 immune cells that, during extravasation, can lead to further loss of integrity for vasculature and 365 the BBB (47, 48). These genes describe the mechanisms that disrupt the vasculature and BBB and allows GBCA to permeate into the tumor. These results corroborate the well-established 366 mechanisms that generate the T1+C signal (14). 367

The biclusters positively associated with T1+C also contain genes describing immune cell infiltration (**Figure 2K**). The VCAM1 pathway members CLDN5, CLDDN23, and PLCG2 work with VCAM1 to signal immune cell transmigration *(48, 49)*. Consistent with our deconvolution

- results, CD163 indicates the presence of anti-inflammatory macrophages that have been
- polarized by IL10 and IL10RA (50, 51) and TREM2 suggests that microglia are also present

It is made available under a CC-BY-NC-ND 4.0 International license .

- 373 *(52).* Together, these macrophages and microglia constitute glioma-associated
- 374 macrophages/microglia (GAMs). Additionally, markers CD2 and CD4 indicate that T-cells join
- anti-inflammatory macrophages as part of the invading immune cell population (53, 54). The co-
- 376 occurrence of immune infiltration and T1+C signal in our results indicate that peripheral immune
- 377 cells are likely crossing into the tumor at the same leaky sites that permit GBCA leakage
- 378 (Figure 2K).
- We observed that genes associated with vasculature and BBB breakdown and the
- transmigration of immune cells increase as T1+C signal increases. While the mechanism driving
- the elevation of T1+C signal due to vasculature and BBB breakdown is well-documented (42–
- 46), it's important to note that immune cell transmigration is a downstream consequence of
- vasculature and BBB breakdown. Meaning that T1+C does not directly quantify immune cell
- infiltration. Consequently, T1+C signal emerges as a valuable surrogate for vasculature and
- BBB breakdown and a meaningful albeit indirect indicator of immune cell infiltration within HGG tumors.

T1+C is an indirect proxy for the proliferation of immune cells

- 388 Genes that increased when T1+C signal intensified were also associated with proliferation-
- related hallmarks of cancer (Figure 1C). The genes from the overlapping biclusters were
- strongly enriched with terms related to T-cell proliferation (**Figures 3A-3C**). This is consistent
- 391 with the discovery of CD4⁺, CD8⁺, and follicular helper T-cell sub-population cell estimates in
- both the MRI and TCGA cohorts (**Figure S2A**). Other enriched pathways describe the process
- by which the T-cell antigen receptors begin the immune response through the tyrosine kinase
- signaling pathway (**Figure 3B**) to initiate the MAPK cascade and downstream ERK1/ERK2 and
- 395 JNK pathways (**Figure 3C**) that result in proliferation (**Figures 3A-3B**) (55–57). The activation
- and proliferation of T-cells supports our original association between T1+C and infiltrating
- immune cells following vasculature and BBB breakdown.

398 T1+C is an indirect proxy for invading immune cell populations

- 399 Genes from the biclusters associated with 'Tissue invasion & metastasis' revealed a range of
- 400 migration-related processes associated with increasing T1+C signal (Figures 4A-4C). These
- 401 functions included immune cell migration, general migration processes, and coagulation
- 402 (Figures 4A-4C). The immune-related migration functions split along distinct cell-type
- 403 categories (**Figure 4A**), and the detection of monocytes (which include macrophages) and T-
- cell migration replicates our association between T1+C and immune infiltration (**Figure 2A-2J**).
- The migration-specific functions support that these immune cell populations are actively
- 406 infiltrating HGGs.

407 Using T1+C as a proxy for immune infiltration within a tumor

- 408 The heterogeneity of HGG tumors is a product of the varied anatomical constraints affecting
- 409 each part of the tumor (e.g., proximity to vasculature, ventricles, skull, or white matter tracts), as
- 410 well as the tumor microenvironment (e.g., overall cellular composition). We collected multiple
- samples from a tumor in the MRI cohort which allowed us to directly observe this heterogeneity
- at the molecular level through the RNA-seq and indirectly through our new noninvasive MRI
- 413 proxies. The six biopsies from the tumor BNI152 are spatially arrayed throughout the CE parts
- of the tumor (Figure 5A & B). For each biopsy of patient BNI152's tumor we show the average

It is made available under a CC-BY-NC-ND 4.0 International license .

- T1+C signal from the voxels containing the biopsy, the expression of three T1+C associated
- bicluster eigengenes, and the expression of a GAM marker gene CD163 (Figure 5C & D). The
- 417 concordance between T1+C signal and the molecular data demonstrates how T1+C can be
- used to spatially map tumor immune cell infiltration (Figure 5D & E) that could be used to assist
- diagnosis, prognosis, or to assess the effect of immunotherapy on HGG tumors.

420 Increased MD and T2W are associated with angiogenesis

- Increased MD and T2W signal were associated with increased expression of a bicluster linked to the 'Sustained angiogenesis' cancer hallmark (**Figure 1C**), suggesting that MD and T2W may be proxies for angiogenesis. The low-strength magnetic field in clinical MRI adeptly captures the swift flow of fluids commonly present in vasculature. Consequently, both MD, which directly
- 425 assesses water movement (3, 58, 59), and T2W, which signifies fluid presence (14), effectively
- 426 capture the presence of vasculature, which is typically the origin of angiogenesis. We validated
- this relationship using a histologically determined measurement of angiogenesis (percent
- angiogenesis) from the TCGA cohort *(36)* (**Table S6**). First, we determined that 15 revised
- 429 biclusters were significantly correlated with histologically determined percent angiogenesis
- 430 (correlation coefficient > 0; p-value \leq 0.01). Expression of four MD and four T2W associated
- biclusters were significantly correlated with percent angiogenesis which was more than
- 432 expected by chance alone (**Figure 6A-D**; MD enrichment p-value = 1.2×10^{-4} ; and T2W
- enrichment p-value = 4.6×10^{-5}). The relationship between angiogenesis and MD and T2W is
- reinforced by the significant overlap with histologically determined angiogenesis.
- 435 Further examination of the genes in the biclusters associated with MD and T2W revealed a wide
- range of biological processes that describe the progression of angiogenesis (Figure 6E). KDR,
- 437 TIE1, and FLT1 are receptors for signals that initiate angiogenesis. ACVRL1 and ROBO4 are
- 438 important receptors for the TGFβ and SLIT pathways, respectively, which promote cell growth
- and angiogenesis. PLXDC1 aids in capillary morphogenesis during the sprouting of new
- 440 vessels. DLL4 and NOTCH4 regulate the growth of new vessels. PDGFR β recruits pericytes to
- support the walls of new blood vessels. CD34, CDH5, ESAM, and MMRN1 indicate the
- presence of endothelial cells lining blood vessel walls. Finally, MYCT1 from the c-MYC pathway
- suggests a swift cell division process, ultimately contributing to the supply of cells necessary for
- 444 vessel growth. In summary, there is significant histological and enriched angiogenic biology
- supporting MD and T2W being useful proxies for angiogenesis in HGG tumors.

446 **MD** and T2W are proxies for cellular migration involved in angiogenesis

- 447 There are also positive associations linking MD and T2W to the biclusters associated with the
- ⁴⁴⁸ 'Tissue invasion & metastasis' cancer hallmark (**Figure 1C**). The genes included in these
- 449 'Tissue invasion & metastasis' associated biclusters were enriched with angiogenesis related
- 450 migratory processes (**Figure 4D**). The significantly enriched functions include the movement of
- 451 endothelial and smooth muscle cells, which are the main cell types in the vasculature (**Figure**
- 452 **4D**). Cell migration involved in angiogenic wound healing and sprouting angiogenesis were also
- 453 significantly enriched (Figure 4D). The formation of angiogenic sprouts requires the
- 454 rearrangement and movement of endothelial and smooth muscle cells. These cell migratory
- 455 functions are consistent with our findings that MD and T2W are linked to 'Sustained
- 456 angiogenesis' and further support their value as proxies for angiogenesis in HGG tumors.

It is made available under a CC-BY-NC-ND 4.0 International license .

457 **Discussion**

In these studies, we demonstrate that the systematic integration of image-localized biopsies

- 459 with omics molecular profiles can reveal aspects of HGG tumor biology using noninvasive MRI
- 460 measurements. Specifically, we provide evidence connecting T1+C signal to tumor immune
- 461 infiltration and MD and T2W signals to angiogenesis. The T1+C MRI measurement directly
- 462 captures the breakdown of vasculature and the BBB through the well-established leakage of
- 463 contrast dye into the tumor. We also found that T1+C indirectly captures immune cell infiltration
- 464 because the breakdown of vasculature and the BBB provides a permissive infiltrative
- 465 environment. Moreover, our investigation revealed that MD and T2W effectively capture the
- 466 intricate biological process of neovascularization. However, the molecular mechanism(s)
- responsible for generating the MRI signal in this context remains an area requiring further
- exploration. To fortify these connections between MRI measurements and tumor biology, we
- validated our findings using histology and by demonstrating the enrichment of well-established
- immune infiltration and angiogenesis pathways in associated gene expression signatures.
- 471 Finally, we illustrated how noninvasive MRI can help understand HGG tumor biology spatially
- across a tumor, establishing a powerful tool for developing more accurate diagnostic,
- 473 prognostic, and treatment efficacy biomarkers for HGG tumors.
- 474 Increased signal from T1+C indicated the presence of anti-inflammatory GAMs, and resting NK
- 475 cells (60). These results are consistent with prior studies showing that HGG tumors are
- immunosuppressive (61–63), and this trait is partially attributed to anti-inflammatory GAMs (61–
- 63). Future studies with spatially matched cohorts that unbiasedly quantify all immune cell types
- 478 from HGG tumors directly using single-cell and spatial transcriptomics techniques will be able to
- better characterize the relative contributions of all immune cell types in areas of elevated T1+C
- 480 signal.
- 481 Recent studies have demonstrated the potential of MRI biomarkers for angiogenesis by linking
- 482 survival benefits from anti-VEGF therapy to the apparent diffusion coefficient (ADC) (64, 65),
- 483 which quantifies the same biophysical phenomenon as MD. Patients whose tumors had higher
- 484 ADC levels showed nearly double the overall survival when treated with anti-VEGF compared to
- those with lower ADC levels. The MRI measurements from the anti-VEGF studies and our MRI
- cohort were taken prior to therapy. Our research offers evidence that ADC effectively quantifies
- 487 angiogenesis, explaining its utility as a biomarker for predicting the response to anti-angiogenic
- therapy. This example showcases how our approach of linking MRI measurements to tumor
- biology can be used to inform clinical studies to develop noninvasive biomarkers.
- 490 T1+C and T2W are commonly used to facilitate many aspects of HGG patient care, including
- 491 initial diagnosis, treatment planning, and response assessment after first-line therapy. Our
- 492 results enhance the utility of these commonly used MRI measurements by showing they predict
- 493 HGG tumor biology. Our discovery that noninvasive MRI measurements are proxies for immune
- 494 cell infiltration and angiogenesis lay the groundwork for capturing more HGG tumor biology.
- 495 Future studies will incorporate new MRI measurement techniques and test their ability to
- 496 capture novel aspects of HGG tumor biology. The long-term goal of this work will allow clinicians
- to noninvasively monitor HGG tumor biology, allowing them to improve diagnosis and prognosis,
- and respond to treatment in real time, so they can adjust treatment and improve patient survival.

It is made available under a CC-BY-NC-ND 4.0 International license .

499 Acknowledgments

- 500 This work was supported by NIH-NINDS Award # 1R01NS123038-01, and 1R01NS119650-01.
- 501 The authors acknowledge the Glioma Biology Protocol Team for their work in collecting the MRI
- 502 cohort and the Cancer Genome Atlas Research Network for the TCGA Pan-Cancer Atlas multi-
- 503 omic patient tumor profiles. We also thank Dr. Benjamin Bartelle and Dr. Scott Beeman for
- sharing their knowledge of MRI. Figures 2K and 5E were created with BioRender.com.

505 Author contributions

- 506 K.R.S., R.F.B., J.L., N.L.T, L.H., and C.L.P. conceived the project. K.R.S, N.L.T, and L.H.
- 507 provided resources through the MRI cohort data. C.L.P. provided resources through the TCGA
- 508 cohort data. E.M.L., L.H. and C.L.P curated data from both studies. E.M.L. and C.L.P.
- 509 conducted formal analysis, investigations, and validations. E.M.L., L.M., L.W., J.L., and C.L.P.
- 510 contributed to visualizations. E.M.L., L.H., and C.L.P. wrote the manuscript. All authors
- 511 contributed to the review and editing of the manuscript. N.T.L., L.H., and C.L.P. contributed to
- supervision and project administration. K.R.S., R.F.B., J.L., N.L.T, L.H., and C.L.P. contributed
- 513 to the funding to support this project.

It is made available under a CC-BY-NC-ND 4.0 International license .

514 **References**

- B. M. Ellingson, M. Bendszus, J. Boxerman, D. Barboriak, B. J. Erickson, M. Smits, S. J. Nelson, E.
 Gerstner, B. Alexander, G. Goldmacher, W. Wick, M. Vogelbaum, M. Weller, E. Galanis, J. Kalpathy-Cramer, L. Shankar, P. Jacobs, W. B. Pope, D. Yang, C. Chung, M. V. Knopp, S. Cha, M. J. van den Bent,
 S. Chang, W. K. A. Yung, T. F. Cloughesy, P. Y. Wen, M. R. Gilbert, Jumpstarting Brain Tumor Drug
 Development Coalition Imaging Standardization Steering Committee, Consensus recommendations
 for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro Oncol* **17**, 1188–1198 (2015).
- P. Karschnia, J. S. Young, A. Dono, L. Häni, T. Sciortino, F. Bruno, S. T. Juenger, N. Teske, R. A. Morshed, A. F. Haddad, Y. Zhang, S. Stoecklein, M. Weller, M. A. Vogelbaum, J. Beck, N. Tandon, S. Hervey-Jumper, A. M. Molinaro, R. Rudà, L. Bello, O. Schnell, Y. Esquenazi, M. I. Ruge, S. J. Grau, M. S. Berger, S. M. Chang, M. van den Bent, J.-C. Tonn, Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. *Neuro Oncol* 25, 940–954 (2023).
- 3. L. S. Hu, S. Ning, J. M. Eschbacher, L. C. Baxter, N. Gaw, S. Ranjbar, J. Plasencia, A. C. Dueck, S. Peng, K.
 A. Smith, P. Nakaji, J. P. Karis, C. C. Quarles, T. Wu, J. C. Loftus, R. B. Jenkins, H. Sicotte, T. M.
 Kollmeyer, B. P. O'Neill, W. Elmquist, J. M. Hoxworth, D. Frakes, J. Sarkaria, K. R. Swanson, N. L. Tran,
 J. Li, J. R. Mitchell, Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. *Neuro Oncol* **19**, 128–137 (2017).
- 4. B. J. Gill, D. J. Pisapia, H. R. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, J. S. Sims,
 M. Banu, A. Dovas, A. F. Teich, S. A. Sheth, G. M. McKhann, M. B. Sisti, J. N. Bruce, P. A. Sims, P.
 Canoll, MRI-localized biopsies reveal subtype-specific differences in molecular and cellular
 composition at the margins of glioblastoma. *Proc Natl Acad Sci U S A* **111**, 12550–12555 (2014).
- 5. L. S. Hu, S. Ning, J. M. Eschbacher, N. Gaw, A. C. Dueck, K. A. Smith, P. Nakaji, J. Plasencia, S. Ranjbar,
 S. J. Price, N. Tran, J. Loftus, R. Jenkins, B. P. O'Neill, W. Elmquist, L. C. Baxter, F. Gao, D. Frakes, J. P.
 Karis, C. Zwart, K. R. Swanson, J. Sarkaria, T. Wu, J. R. Mitchell, J. Li, Multi-Parametric MRI and Texture
 Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. *PLoS One* 10,
 e0141506 (2015).
- 6. N. Gaw, A. Hawkins-Daarud, L. S. Hu, H. Yoon, L. Wang, Y. Xu, P. R. Jackson, K. W. Singleton, L. C.
 Baxter, J. Eschbacher, A. Gonzales, A. Nespodzany, K. Smith, P. Nakaji, J. R. Mitchell, T. Wu, K. R.
 Swanson, J. Li, Integration of machine learning and mechanistic models accurately predicts variation
 in cell density of glioblastoma using multiparametric MRI. *Sci Rep* 9, 10063 (2019).
- 7. P. D. Chang, H. R. Malone, S. G. Bowden, D. S. Chow, B. J. A. Gill, T. H. Ung, J. Samanamud, Z. K.
 Englander, A. M. Sonabend, S. A. Sheth, G. M. McKhann, M. B. Sisti, L. H. Schwartz, A. Lignelli, J.
 Grinband, J. N. Bruce, P. Canoll, A Multiparametric Model for Mapping Cellularity in Glioblastoma
 Using Radiographically Localized Biopsies. *AJNR Am J Neuroradiol* 38, 890–898 (2017).
- 8. J. E. Park, H. S. Kim, Y. Jo, R.-E. Yoo, S. H. Choi, S. J. Nam, J. H. Kim, Radiomics prognostication model in
 glioblastoma using diffusion- and perfusion-weighted MRI. *Sci Rep* **10**, 4250 (2020).
- 9. N. Beig, K. Bera, P. Prasanna, J. Antunes, R. Correa, S. Singh, A. Saeed Bamashmos, M. Ismail, N.
 Braman, R. Verma, V. B. Hill, V. Statsevych, M. S. Ahluwalia, V. Varadan, A. Madabhushi, P. Tiwari,

- Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with
 Biological Processes in Glioblastoma. *Clin Cancer Res* 26, 1866–1876 (2020).
- 10. H. Akbari, L. Macyszyn, X. Da, M. Bilello, R. L. Wolf, M. Martinez-Lage, G. Biros, M. Alonso-Basanta, D.
 M. Oll Rourke, C. Davatzikos, Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging
 Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma. *Neurosurgery* 78, 572–
 580 (2016).
- 11. L. S. Hu, L. Wang, A. Hawkins-Daarud, J. M. Eschbacher, K. W. Singleton, P. R. Jackson, K. ClarkSwanson, C. P. Sereduk, S. Peng, P. Wang, J. Wang, L. C. Baxter, K. A. Smith, G. L. Mazza, A. M. Stokes,
 B. R. Bendok, R. S. Zimmerman, C. Krishna, A. B. Porter, M. M. Mrugala, J. M. Hoxworth, T. Wu, N. L.
 Tran, K. R. Swanson, J. Li, Uncertainty quantification in the radiogenomics modeling of EGFR
 amplification in glioblastoma. *Sci Rep* **11**, 3932 (2021).
- 12. H. R. Cho, H. Jeon, C.-K. Park, S.-H. Park, S. H. Choi, Radiogenomics Profiling for Glioblastoma-related
 Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis. *Sci Rep* 8,
 16022 (2018).
- 567 13. L. S. Hu, F. D'Angelo, T. M. Weiskittel, F. P. Caruso, S. P. Fortin Ensign, M. R. Blomquist, M. J. Flick, L. 568 Wang, C. P. Sereduk, K. Meng-Lin, G. De Leon, A. Nespodzany, J. C. Urcuyo, A. C. Gonzales, L. Curtin, 569 E. M. Lewis, K. W. Singleton, T. Dondlinger, A. Anil, N. B. Semmineh, T. Noviello, R. A. Patel, P. Wang, 570 J. Wang, J. M. Eschbacher, A. Hawkins-Daarud, P. R. Jackson, I. S. Grunfeld, C. Elrod, G. L. Mazza, S. C. 571 McGee, L. Paulson, K. Clark-Swanson, Y. Lassiter-Morris, K. A. Smith, P. Nakaji, B. R. Bendok, R. S. 572 Zimmerman, C. Krishna, D. P. Patra, N. P. Patel, M. Lyons, M. Neal, K. Donev, M. M. Mrugala, A. B. 573 Porter, S. C. Beeman, T. R. Jensen, K. M. Schmainda, Y. Zhou, L. C. Baxter, C. L. Plaisier, J. Li, H. Li, A. 574 Lasorella, C. C. Quarles, K. R. Swanson, M. Ceccarelli, A. lavarone, N. L. Tran, Integrated molecular and 575 multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat 576 Commun 14, 6066 (2023).
- 14. L. S. Hu, A. Hawkins-Daarud, L. Wang, J. Li, K. R. Swanson, Imaging of intratumoral heterogeneity in
 high-grade glioma. *Cancer Lett* 477, 97–106 (2020).
- 15. L. A. Mohsen, V. Shi, R. Jena, J. H. Gillard, S. J. Price, Diffusion tensor invasive phenotypes can predict
 progression-free survival in glioblastomas. *Br J Neurosurg* 27, 436–441 (2013).
- 16. R. F. Barajas, J. J. Phillips, R. Parvataneni, A. Molinaro, E. Essock-Burns, G. Bourne, A. T. Parsa, M. K.
 Aghi, M. W. McDermott, M. S. Berger, S. Cha, S. M. Chang, S. J. Nelson, Regional variation in
 histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with
 anatomic and physiologic MR Imaging. *Neuro Oncol* 14, 942–954 (2012).
- 17. C. L. Plaisier, S. O'Brien, B. Bernard, S. Reynolds, Z. Simon, C. M. Toledo, Y. Ding, D. J. Reiss, P. J.
 Paddison, N. S. Baliga, Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using
 Systems Genetics Network Analysis. *Cell Syst* 3, 172–186 (2016).
- 18. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. *Cell* **100**, 57–70 (2000).
- 19. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).

It is made available under a CC-BY-NC-ND 4.0 International license .

- 20. C. L. Plaisier, M. Pan, N. S. Baliga, A miRNA-regulatory network explains how dysregulated miRNAs
 perturb oncogenic processes across diverse cancers. *Genome Res.* 22, 2302–2314 (2012).
- 592 21. B. M. Alexander, T. F. Cloughesy, Adult Glioblastoma. J Clin Oncol 35, 2402–2409 (2017).
- 593 22. M. Jenkinson, C. F. Beckmann, T. E. J. Behrens, M. W. Woolrich, S. M. Smith, FSL. *Neuroimage* 62, 782–790 (2012).
- 595 23. S. J. Price, R. Jena, N. G. Burnet, P. J. Hutchinson, A. F. Dean, A. Peña, J. D. Pickard, T. A. Carpenter, J.
 596 H. Gillard, Improved delineation of glioma margins and regions of infiltration with the use of diffusion
 597 tensor imaging: an image-guided biopsy study. *AJNR Am J Neuroradiol* 27, 1969–1974 (2006).
- 598 24. M. McCormick, X. Liu, J. Jomier, C. Marion, L. Ibanez, ITK: enabling reproducible research and open
 599 science. *Front Neuroinform* 8, 13 (2014).
- 25. F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer,
 R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, É. Duchesnay,
 Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* 12, 2825–2830
 (2011).
- 26. S. Seabold, J. Perktold, in *Proceedings of the 9th Python in Science Conference*, S. van der Walt, J.
 Millman, Eds. (2010), pp. 92–96.

606 27. V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T.-H. Ou Yang, E. Porta-Pardo, G. F. Gao, 607 C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, 608 F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. 609 Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. 610 Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pedamallu, S. Bullman, 611 A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin, Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. 612 613 Disis, B. G. Vincent, I. Shmulevich, The Immune Landscape of Cancer. Immunity 48, 812-830.e14 614 (2018).

- 28. J. Liu, T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, A. J. Kovatich, C. C.
 Benz, D. A. Levine, A. V. Lee, L. Omberg, D. M. Wolf, C. D. Shriver, V. Thorsson, Cancer Genome Atlas
 Research Network, H. Hu, An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive HighQuality Survival Outcome Analytics. *Cell* **173**, 400-416.e11 (2018).
- 29. W. C. Rutledge, J. Kong, J. Gao, D. A. Gutman, L. A. D. Cooper, C. Appin, Y. Park, L. Scarpace, T.
 Mikkelsen, M. L. Cohen, K. D. Aldape, R. E. McLendon, N. L. Lehman, C. R. Miller, M. J. Schniederjan,
 C. W. Brennan, J. H. Saltz, C. S. Moreno, D. J. Brat, Tumor-infiltrating lymphocytes in glioblastoma are
 associated with specific genomic alterations and related to transcriptional class. *Clin. Cancer Res.* 19,
 4951–4960 (2013).
- 30. A. M. Newman, C. B. Steen, C. L. Liu, A. J. Gentles, A. A. Chaudhuri, F. Scherer, M. S. Khodadoust, M.
 S. Esfahani, B. A. Luca, D. Steiner, M. Diehn, A. A. Alizadeh, Determining cell type abundance and
 expression from bulk tissues with digital cytometry. *Nat Biotechnol* **37**, 773–782 (2019).

- 627 31. N. Abdelfattah, P. Kumar, C. Wang, J.-S. Leu, W. F. Flynn, R. Gao, D. S. Baskin, K. Pichumani, O. B.
- 628 Ijare, S. L. Wood, S. Z. Powell, D. L. Haviland, B. C. Parker Kerrigan, F. F. Lang, S. S. Prabhu, K. M.
- 629 Huntoon, W. Jiang, B. Y. S. Kim, J. George, K. Yun, Single-cell analysis of human glioma and immune 630 cells identifies S100A4 as an immunotherapy target. *Nat Commun* **13**, 767 (2022).
- 32. E. Friebel, K. Kapolou, S. Unger, N. G. Núñez, S. Utz, E. J. Rushing, L. Regli, M. Weller, M. Greter, S.
 Tugues, M. C. Neidert, B. Becher, Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific
 Instruction of Tissue-Invading Leukocytes. *Cell* 181, 1626-1642.e20 (2020).
- 33. F. Klemm, R. R. Maas, R. L. Bowman, M. Kornete, K. Soukup, S. Nassiri, J.-P. Brouland, C. A. lacobuzioDonahue, C. Brennan, V. Tabar, P. H. Gutin, R. T. Daniel, M. E. Hegi, J. A. Joyce, Interrogation of the
 Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. *Cell* 181, 1643-1660.e17 (2020).
- 638 34. C. Neftel, J. Laffy, M. G. Filbin, T. Hara, M. E. Shore, G. J. Rahme, A. R. Richman, D. Silverbush, M. L. 639 Shaw, C. M. Hebert, J. Dewitt, S. Gritsch, E. M. Perez, L. N. Gonzalez Castro, X. Lan, N. Druck, C. 640 Rodman, D. Dionne, A. Kaplan, M. S. Bertalan, J. Small, K. Pelton, S. Becker, D. Bonal, Q.-D. Nguyen, R. 641 L. Servis, J. M. Fung, R. Mylvaganam, L. Mayr, J. Gojo, C. Haberler, R. Geyeregger, T. Czech, I. Slavc, B. V. Nahed, W. T. Curry, B. S. Carter, H. Wakimoto, P. K. Brastianos, T. T. Batchelor, A. Stemmer-642 643 Rachamimov, M. Martinez-Lage, M. P. Frosch, I. Stamenkovic, N. Riggi, E. Rheinbay, M. Monje, O. 644 Rozenblatt-Rosen, D. P. Cahill, A. P. Patel, T. Hunter, I. M. Verma, K. L. Ligon, D. N. Louis, A. Regev, B. 645 E. Bernstein, I. Tirosh, M. L. Suvà, An Integrative Model of Cellular States, Plasticity, and Genetics for
- 646 Glioblastoma. *Cell* **178**, 835-849.e21 (2019).
- 35. M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L.
 Jenkins, K. M. Jagodnik, A. Lachmann, M. G. McDermott, C. D. Monteiro, G. W. Gundersen, A.
 Ma'ayan, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res* 44, W90-97 (2016).
- 36. L. A. D. Cooper, D. A. Gutman, C. Chisolm, C. Appin, J. Kong, Y. Rong, T. Kurc, E. G. Van Meir, J. H.
 Saltz, C. S. Moreno, D. J. Brat, The tumor microenvironment strongly impacts master transcriptional
 regulators and gene expression class of glioblastoma. *Am J Pathol* 180, 2108–2119 (2012).
- 654 37. C. W. Brennan, R. G. W. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. R. Salama, S. Zheng, D. 655 Chakravarty, J. Z. Sanborn, S. H. Berman, R. Beroukhim, B. Bernard, C.-J. Wu, G. Genovese, I. 656 Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna, S. A. Shukla, G. Ciriello, W. K. Yung, W. Zhang, C. 657 Sougnez, T. Mikkelsen, K. Aldape, D. D. Bigner, E. G. Van Meir, M. Prados, A. Sloan, K. L. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D. W. Andrews, A. Guha, M. Iacocca, B. P. O'Neill, G. Foltz, 658 659 J. Myers, D. J. Weisenberger, R. Penny, R. Kucherlapati, C. M. Perou, D. N. Hayes, R. Gibbs, M. Marra, 660 G. B. Mills, E. Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P. W. 661 Laird, D. Haussler, G. Getz, L. Chin, TCGA Research Network, The somatic genomic landscape of 662 glioblastoma. Cell 155, 462-477 (2013).
- 38. S. Zhao, W.-P. Fung-Leung, A. Bittner, K. Ngo, X. Liu, Comparison of RNA-Seq and microarray in
 transcriptome profiling of activated T cells. *PLoS One* 9, e78644 (2014).
- 39. W. Zhang, Y. Yu, F. Hertwig, J. Thierry-Mieg, W. Zhang, D. Thierry-Mieg, J. Wang, C. Furlanello, V.
 Devanarayan, J. Cheng, Y. Deng, B. Hero, H. Hong, M. Jia, L. Li, S. M. Lin, Y. Nikolsky, A. Oberthuer, T.
 Qing, Z. Su, R. Volland, C. Wang, M. D. Wang, J. Ai, D. Albanese, S. Asgharzadeh, S. Avigad, W. Bao, M.

668	Bessarabova,	М. Н	Brilliant,	B. Brors, I	M. Chierici,	TM. Chu,	, J. Zhang, R. G	i. Grundy, M. M. He, S.	
-----	--------------	------	------------	-------------	--------------	----------	------------------	-------------------------	--

- 669 Hebbring, H. L. Kaufman, S. Lababidi, L. J. Lancashire, Y. Li, X. X. Lu, H. Luo, X. Ma, B. Ning, R. Noguera,
- 670 M. Peifer, J. H. Phan, F. Roels, C. Rosswog, S. Shao, J. Shen, J. Theissen, G. P. Tonini, J. Vandesompele,
- 671 P.-Y. Wu, W. Xiao, J. Xu, W. Xu, J. Xuan, Y. Yang, Z. Ye, Z. Dong, K. K. Zhang, Y. Yin, C. Zhao, Y. Zheng, R.
- D. Wolfinger, T. Shi, L. H. Malkas, F. Berthold, J. Wang, W. Tong, L. Shi, Z. Peng, M. Fischer,
- 673 Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. *Genome Biol*674 **16**, 133 (2015).
- 40. N. Beig, J. Patel, P. Prasanna, V. Hill, A. Gupta, R. Correa, K. Bera, S. Singh, S. Partovi, V. Varadan, M.
 Ahluwalia, A. Madabhushi, P. Tiwari, Radiogenomic analysis of hypoxia pathway is predictive of
 overall survival in Glioblastoma. *Sci Rep* 8, 7 (2018).
- 41. A. Salvalaggio, E. Silvestri, G. Sansone, L. Pinton, S. Magri, C. Briani, M. Anglani, G. Lombardi, V.
 Zagonel, A. Della Puppa, S. Mandruzzato, M. Corbetta, A. Bertoldo, Magnetic Resonance Imaging
 Correlates of Immune Microenvironment in Glioblastoma. *Front Oncol* 12, 823812 (2022).
- 42. G. P. Cribaro, E. Saavedra-López, L. Romarate, I. Mitxitorena, L. R. Díaz, P. V. Casanova, M. RoigMartínez, J. M. Gallego, A. Perez-Vallés, C. Barcia, Three-dimensional vascular microenvironment
 landscape in human glioblastoma. *Acta Neuropathol Commun* 9, 24 (2021).
- 43. B. K. Ahir, H. H. Engelhard, S. S. Lakka, Tumor Development and Angiogenesis in Adult Brain Tumor:
 Glioblastoma. *Mol Neurobiol* 57, 2461–2478 (2020).
- 44. J. N. Sarkaria, L. S. Hu, I. F. Parney, D. H. Pafundi, D. H. Brinkmann, N. N. Laack, C. Giannini, T. C.
 Burns, S. H. Kizilbash, J. K. Laramy, K. R. Swanson, T. J. Kaufmann, P. D. Brown, N. Y. R. Agar, E.
 Galanis, J. C. Buckner, W. F. Elmquist, Is the blood-brain barrier really disrupted in all glioblastomas?
 A critical assessment of existing clinical data. *Neuro Oncol* 20, 184–191 (2018).
- 45. D. Hambardzumyan, G. Bergers, Glioblastoma: Defining Tumor Niches. *Trends Cancer* 1, 252–265
 (2015).
- 46. J. J. Connell, G. Chatain, B. Cornelissen, K. A. Vallis, A. Hamilton, L. Seymour, D. C. Anthony, N. R.
 Sibson, Selective permeabilization of the blood-brain barrier at sites of metastasis. *J Natl Cancer Inst*105, 1634–1643 (2013).
- 47. A. Haarmann, E. Nowak, A. Deiß, S. van der Pol, C.-M. Monoranu, G. Kooij, N. Müller, P. van der Valk,
 G. Stoll, H. E. de Vries, F. Berberich-Siebelt, M. Buttmann, Soluble VCAM-1 impairs human brain
 endothelial barrier integrity via integrin α-4-transduced outside-in signalling. *Acta Neuropathol* 129,
 639–652 (2015).
- 48. J. M. Cook-Mills, M. E. Marchese, H. Abdala-Valencia, Vascular cell adhesion molecule-1 expression
 and signaling during disease: regulation by reactive oxygen species and antioxidants. *Antioxid Redox Signal* 15, 1607–1638 (2011).
- 49. F. Belinky, N. Nativ, G. Stelzer, S. Zimmerman, T. Iny Stein, M. Safran, D. Lancet, PathCards: multi source consolidation of human biological pathways. *Database (Oxford)* 2015, bav006 (2015).

- 50. H. Li, D. Wang, B. Yi, H. Cai, Z. Xi, X. Lou, Z. Li, Comprehensive Analysis of CD163 as a Prognostic
 Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme. *Biomed Res Int* 2021, 8357585 (2021).
- 51. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol* **25**, 677–686 (2004).
- 52. N. Geribaldi-Doldán, C. Fernández-Ponce, R. N. Quiroz, I. Sánchez-Gomar, L. G. Escorcia, E. P.
 Velásquez, E. N. Quiroz, The Role of Microglia in Glioblastoma. *Front Oncol* 10, 603495 (2020).
- 53. C. Binder, F. Cvetkovski, F. Sellberg, S. Berg, H. Paternina Visbal, D. H. Sachs, E. Berglund, D.
 Berglund, CD2 Immunobiology. *Front Immunol* **11**, 1090 (2020).
- 54. V. Golubovskaya, L. Wu, Different Subsets of T Cells, Memory, Effector Functions, and CAR-T
 Immunotherapy. *Cancers (Basel)* 8, 36 (2016).
- 55. D. Cantrell, T cell antigen receptor signal transduction pathways. *Annu Rev Immunol* 14, 259–274
 (1996).
- 56. C. A. J. Jr, P. Travers, M. Walport, M. J. Shlomchik, C. A. J. Jr, P. Travers, M. Walport, M. J. Shlomchik, *Immunobiology* (Garland Science, ed. 5th, 2001).
- 57. K. Adachi, M. M. Davis, T-cell receptor ligation induces distinct signaling pathways in naive vs.
 antigen-experienced T cells. *Proc Natl Acad Sci U S A* **108**, 1549–1554 (2011).
- 58. L. Tang, X. J. Zhou, Diffusion MRI of cancer: From low to high b-values. *J Magn Reson Imaging* 49, 23–40 (2019).
- 59. C. Han, L. Zhao, S. Zhong, X. Wu, J. Guo, X. Zhuang, H. Han, A comparison of high b-value vs standard
 b-value diffusion-weighted magnetic resonance imaging at 3.0^{II}T for medulloblastomas. *Br J Radiol*88, 20150220 (2015).
- 60. C. N. Kersch, L. L. Muldoon, C. J. Claunch, R. Fu, D. Schwartz, S. Cha, J. Starkey, E. A. Neuwelt, R. F.
 Barajas, Multiparametric magnetic resonance imaging discerns glioblastoma immune
 microenvironmental heterogeneity. *Neuroradiol J*, 19714009231163560 (2023).
- 61. B. T. Himes, P. A. Geiger, K. Ayasoufi, A. G. Bhargav, D. A. Brown, I. F. Parney, Immunosuppression in
 Glioblastoma: Current Understanding and Therapeutic Implications. *Front Oncol* 11, 770561 (2021).
- 62. Z. Zhu, H. Zhang, B. Chen, X. Liu, S. Zhang, Z. Zong, M. Gao, PD-L1-Mediated Immunosuppression in
 Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated
 Macrophages. *Front Immunol* **11**, 588552 (2020).
- 63. E. K. Nduom, M. Weller, A. B. Heimberger, Immunosuppressive mechanisms in glioblastoma. *Neuro Oncol* 17 Suppl 7, vii9–vii14 (2015).
- 64. K. S. Patel, R. G. Everson, J. Yao, C. Raymond, J. Goldman, J. Schlossman, J. Tsung, C. Tan, W. B. Pope,
 M. S. Ji, N. T. Nguyen, A. Lai, P. L. Nghiemphu, L. M. Liau, T. F. Cloughesy, B. M. Ellingson, Diffusion

It is made available under a CC-BY-NC-ND 4.0 International license .

- 738 Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or
- Surgery in Recurrent Glioblastoma With Large Tumor Burden. *Neurosurgery* **87**, 931–938 (2020).
- 740 65. B. M. Ellingson, E. R. Gerstner, M. Smits, R. Y. Huang, R. Colen, L. E. Abrey, D. T. Aftab, G. M. Schwab,
- 741 C. Hessel, R. J. Harris, A. Chakhoyan, R. Gahrmann, W. B. Pope, K. Leu, C. Raymond, D. C. Woodworth,
- 742J. de Groot, P. Y. Wen, T. T. Batchelor, M. J. van den Bent, T. F. Cloughesy, Diffusion MRI Phenotypes
- 743 Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging
- Evidence from Phase II Trials. *Clin Cancer Res* **23**, 5745–5756 (2017).

It is made available under a CC-BY-NC-ND 4.0 International license .

746 Figure legends

- **Figure 1**. Associating MRI measurements with HGG tumor biology. (**A**) Biclusters from the
- gbmSYGNAL network were refined using RNA-seq data from the MRI cohort and were then
- used to associate MRI measurements and HGG tumor biology. (B) Number of biclusters
- 750 associated with MRI measurements separated by positive and negative relationships with MRI
- 751 signal. The Total column in yellow denotes number of biclusters associated with any MRI
- 752 measurement, regardless of sign. (C) Number of biclusters associated with MRI and hallmarks
- of cancer separated by hallmark. Significant enrichment of MRI and hallmarks of cancer
- associated biclusters are denoted by a cyan outline. (D) Number of biclusters associated with
- 755 MRI and patient survival separated by relationship with prognosis. Significant enrichment
- 756 between MRI and patient survival associated biclusters are denoted by an orange outline.
- **Figure 2**. Validating the association of T1+C with infiltrating immune cells. Histologically
- determined TIL levels were tested for association with bicluster eigengene expression using a
- 759 T-test for biclusters positively (A) and negatively (B) associated with MRI measurements.
- Significant associations with a bicluster are shown with darker red (A) or green (B) colors.
- 761 Hypergeometric enrichment between TIL and positively (**C**) and negatively (**D**) MRI associated
- biclusters. "Pos. stat." indicates a positive T-statistic and "Neg. stat." indicates a negative T-
- statistic. Boxes with a dashed line indicate zero overlapping biclusters (z.o.). Associations
- between infiltrating immune cell estimates and T1+C bicluster eigengenes for T-cells (E), NK
- cells (**F**), and macrophages/microglia (**G**) using a MEM for the MRI cohort (left y-axis) and using
- correlation for the TCGA cohort (right y-axis). Significantly associated biclusters from the MRI
- cohort are denoted by darker blue and from the TCGA cohort are denoted by darker red.
- 768 Hypergeometric enrichment between biclusters positively associated with T1+C and biclusters
- associated with T-cells (H), NK cells (I), and macrophages/microglia (J). "Pos. assoc." indicates
- a positive association and "Neg. assoc." indicates an inverse association. "Pro-inflamm."
- indicates pro-inflammatory macrophages/microglia and "Anti-inflamm." indicates anti-
- inflammatory macrophages/microglia. (K) Schematic of vasculature and BBB breakdown
- characteristic of HGG tumors. Green text represents the genes and functions included in T1+Cbiclusters.
- **Figure 3**. Proliferation-related biological processes enriched in imaging associated bicluster
- genes. Grouped by immune (A), growth (B), signaling (C), and vessel (D) related proliferation
 processes.
- Figure 4. Invasion-related biological processes enriched in imaging associated bicluster genes.
 Grouped by immune (A), general (B), blood (C), and vessel (D) related migration processes.
- 780 **Figure 5**. MRI captures immune infiltration across tumor biopsies. (A) Biopsy locations (red)
- within the tumor (yellow). (**B**) Z-coordinate of the slice of the MRI capture for each sample. (**C**)
- T1+C MRI image slice showing the biopsy location of each sample. (**D**) Percentiles of MRI
- signal, bicluster expression, and gene expression related to immune infiltration for each sample.
- 784 (E) Percentiles of MRI signal, bicluster expression, and gene expression related to immune
- infiltration for each sample overlaid onto tumor spatial locations.

- **Figure 6**. MD and T2W are associated with angiogenesis. Correlation between angiogenesis
- percentage and biclusters positively (A) and negatively (B) associated with MRI measurements.
- 788 Hypergeometric enrichment between biclusters associated with angiogenesis percentage and
- biclusters positively (C) and negatively (D) associated with each MRI measurement. "Pos. coef."
- ⁷⁹⁰ indicates a positive correlation and "Neg. coef." indicates an inverse correlation. Boxes with a
- 791 dashed line indicate zero overlapping biclusters (z.o.). (E) MD and T2W biclusters contain
- 792 genes (purple) from sprouting angiogenesis.

It is made available under a CC-BY-NC-ND 4.0 International license .

793 Figures

794 **Figure 1.**



	🔲 = Sig. hallmark enrichment			mpl	Pos VIRI as	sitive sociat	lons		mpl									
	🔟 = Sig. survival enrichment	Total	Ī	FA	MD	T1+C	T2W	Ī	FA	MD	T1+C	T2W						
3	MRI-associated	274		43	16	191	12		1	17	17	58						
;	Sustained angiogenesis	3		0	1	0	1		0	1	0	0	-60					
Biclusters assocated with MRI & halimark of cancer	Insensitivity to antigrowth signals	16		2	0	10	0		0	0	1	2	- 40					
	Self sufficiency in growth signals	17		2	0	11	0		0	0	1	2	-20					
	Evading immune detection	58		2	0	68	0		٥	0	0	4						
	Tumor promoting inflammation	58		2	0	58	0		0	0	0	4	- 10					
	Tiasue invesion & melastrais	12		1	5	3	6		1	0	0	1						
	Evading apoptosis	3		0	0	0	1		1	0	0	0	-0					
	Reprogramming energy metabolism	1		0	0	0	0	Γ	0	0	0	0						
	Genome instability & mutation	7		Γ	Γ	Γ	Γ	Г	Г	0	0	0	0		0	0	0	0
	Limitiess replicative potential	0		0	0	0	0		0	0	0	0	-0					
)	Associated to worse prognosis	198	t	17	2	104	2		0	1	1	20						
	Associated to better prognosis	5	Γ	0	0	0	0		0	0	0	0						



It is made available under a CC-BY-NC-ND 4.0 International license .

799 Figure 3.

			T'NACU	«P	*	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				
Α							- T-cell proliferation			
	E	T-cells					- Regulation of T-cell proliferation			
	ratic						- Positive regulation of T-cell proliferation			
	life	B-cells					- Positive regulation of B-cell proliferation			
	pro	Lymphocytes					- Positive regulation of lymphocyte proliteration			
	ted						- Regulation of immune response			
	rela	Immune response					- Positive regulation of immune response			
	ne-						- Immune response-regulating cell surface receptor signaling pathway			
	Ĩ	Signaling					- immune response-activating call aurface receptor signaling pathway			
	≞	orginaling					 Antigen receptor-mediated signaling pathway 			
							- Positive regulation of HospaB/NF-kappaB signaling			
В							- Transmembrane receptor protein tyrosine kinese signaling pathway			
		Designation astherage					- Transmembrane receptor protein serine/threonine kinase signaling patiw	ay	1	
		r iviicialite pallways					- Positive regulation of phosphaticlylinositol 3-kinase signaling			
							- Positive regulation of protein kinase B signaling			
	wth		- Regulation of cell proliferation			- Regulation of cell proliferation	-	1.5		
	22	Regulation					- Positive regulation of cell proliferation			눙
							- Calitier response to growth factor stimulus	-	2	ğ
							- Positive regulation of neural precursor cell proliferation			Ï
							- Negative regulation of cell cycle phase transition			ą
		Migration					- Positive regulation of chemotaxis	-	25	
С							- Regulation of MAPK cascade			ē P
							- Positive regulation of MAPK cascade	-	3	Ż
							- Positive regulation of stress-activated MAPK cascade			5
		Response to stress					- Positive regulation of MAP kinase activity			
							- Positive regulation of ERK1 and ERK2 cascade	-	8.6	
							- Positive regulation of JNK cascade			
	5			<u> </u>			- Poetros regulation of anexas-activated protein ichase signaling cascade Resilies manufating of anexastatic simulian activation		4	
	alin						- Loanne uednamou ou stothnong aiturauit banunaà			
	ign		_				- Cellular response to cytokine stimulus			
	ŝ						- Caluar response to organic substance			
							- Cytourio-Inclinated signaling partnery			
		Response to cytokines		-			- Cooking a molecular and a second se			
							- Regulation of signal transduction			
							- Positive regulation of signal transduction			
							- Negative regulation of signal transduction			
							- Positive regulation of intracellular signel transduction			
D							- - Regulation of endothelial cell proliferation			
-	se	Endothelial					- Positive regulation of endothelial cell proliferation			
	/es:						- Regulation of amooth muncle cell proliferation			
		Smooth muscle					- Positive regulation of smooth muscle cell profileration			
			ىكى ا	49	s S	*				
			<u> </u>	•	•	۲ ۲				

It is made available under a CC-BY-NC-ND 4.0 International license .

801 Figure 4.



It is made available under a CC-BY-NC-ND 4.0 International license .

803 **Figure 5.**



It is made available under a CC-BY-NC-ND 4.0 International license .

805 Figure 6.





	= Sig. hallmark enrichment			mpl	Positive mpMRI associations					Negative mpMRI associations					
socaited with ark of cancer	= Sig. survival enrichment	Total		FA	MD	T1+C	T2W		FA	MD	T1+C	T2W			
	MRI-associated	274		43	16	191	12		1	17	17	58			
	Sustained angiogenesis	3		0	1	0	1		0	1	0	0		- 60	
	Insensitivity to antigrowth signals	16		2	0	10	0		0	0	1	2		- 30	Z
	Self sufficiency in growth signals	17		2	0	11	0		0	0	1	2		- 20	
	Evading immune detection	58		2	0	58	0		0	0	0	4			a D C C C C C C
	Tumor promoting inflammation	58		2	0	58	0		0	0	0	4		- 10	c
as Imá	Tissue invasion & metastasis	12		1	5	3	6		1	0	0	1	-5	E	
Biclusters MRI & hal	Evading apoptosis	3		0	0	0	1		1	0	0	0		-5	Sin's
	Reprogramming energy metabolism	1		0	0	0	0		0	0	0	0			e le
	Genome instability & mutation	7	 	0	0	0	0		0	0	0	0			U
	Limitless replicative potential	0		0	0	0	0		0	0	0	0		_ 0	
							1			I			1	-0	
	Associated to worse prognosis	198		17	2	104	2		0	1	1	20			
	Associated to better prognosis	5		0	0	0	0		0	0	0	0			

Β

С

D











